重组人红细胞生成素治疗恶性肿瘤贫血的临床观察

详细信息

Clinical Observation of Erythropoietin in Treating the Malignant Tumour Anemia

Department of Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430023, China

摘要: 目的观察重组人红细胞生成素（rHuEpo）治疗恶性肿瘤贫（MTA）的效果。方法治疗组患者接受rHuEpo皮下注射，10000）U，隔日1次，疗程8周。疗效不明显或有缺铁实验室证据的患者加用琥珀酸亚铁0．1g口服，每日3次。治疗中如患者血红蛋白≤80g／L，可考虑给予输血。对照组不给予rHuEpo，其他同治疗组。结果治疗组有22例（73．3％）血红蛋白上升〉20g／L，对照组仅4例（13．3％）血红蛋白上升〉20g／L，两组有效率差异有统计学意义（P〈0.01）。结论 rHuEpo治疗MTA安全有效。
- 恶性肿瘤贫血 /
- 红细胞生成素 /
- 恶性肿瘤
Abstract: Objective 　To observe the effect of recombinant human erythropietin ( rHuEpo) in t reating malignant tumour anemia (MTA) . Methods 　Thirty cases of treated group were treated with rHuEpo 10000 U, qod, lasted for 8 weeks . Thirty cases of control group were treated with support cares and the blood transfusion. Results 　The overall response rates of treated and control group were 73. 3 %(22/30) and 13. 3 % (4/ 30) respectively, and the increased Hb of treated group is more higher than that of control group ( P < 0. 01) . Conclusion 　rHuEpo is effective and safe in treating MTA.
- Malignant tumor anemia /
- Recombinant human erythropoietin /
- Malignant tumor